Clinical trials in Saint-Cloud – page 212

3 344 clinical trials in Saint-Cloud, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Saint-Cloud at a glance

3 344

clinical trials

Research sites1

Quick filters

3 344 trials in Saint-Cloud

Open in trial search

Prostate cancer metastatic

Not recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

France

Participants:0–17 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

France

Participants:0–17 years · 18–64 years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alkylating agents
Sponsor:Geron Corp.

Contact Research Centre

Chronic cutaneous lupus erythematosus+2

Not recruiting

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational

France

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Neoplasm malignant

Not recruiting

Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo

Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug

France

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Neoplasm

Not recruiting

Study of BMS-986253 with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drug

Study of BMS-986253 with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Cervix carcinoma

Not recruiting

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Aldesleukin
Sponsor:Iovance Biotherapeutics Inc.

Contact Research Centre

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Folic Acid
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

Registered drug

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Saint-Cloud

What the registry says about research in the country

01 Blood Cancer Research

Innovative trials focusing on lymphoma and multiple myeloma treatments, including studies of novel therapies like duvelisib for T-cell lymphoma and odronextamab for follicular lymphoma.

B-Cell Lymphomas
Multiple Myeloma
T-Cell Lymphomas

Several studies are evaluating combination therapies and comparing new treatment approaches against standard care.

02 Breast Cancer Studies

Comprehensive research into various types of breast cancer, with particular focus on hormone receptor-positive and triple-negative variants. Studies include early detection methods and novel therapeutic combinations.

HR+/HER2- Advanced Breast Cancer
Triple-Negative Breast Cancer
Early-Stage Disease

Trials incorporate innovative approaches like ctDNA monitoring and targeted therapies.

03 Advanced Cancer Therapies

Research focusing on targeted therapies for various advanced cancers, including studies of biliary tract cancer and non-small cell lung cancer treatments.

Lung Cancer
Biliary Tract Cancer
Prostate Cancer

Emphasis on immunotherapy combinations and precision medicine approaches.

Back to France All countries